Objective: Valvular heart disease is common in patients with rheumatoid arthritis (RA).
| INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune condition resulting in systemic inflammation. 1 Predominantly affecting females, RA has a lifetime risk of 3.6% in females and 1.7% in males, and the risk increases with age. 2 Prior investigations have described the detrimental effect of RA on the various components of the cardiovascular system. For instance, the increased mortality in the RA population is primarily due to accelerated coronary atherosclerosis and resultant ischemic heart disease 3 that cannot be attributed to traditional risk factors alone. 4 Indeed, the frequency of myocardial infarction in the RA population is increased twofold compared with that in age-matched persons. 5 Also, RA is associated with an increased risk of congestive heart failure, 6 the specific pathophysiologic mechanism for this finding remaining
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elusive. Along with the coronary vasculature and the myocardium, the pericardium also seems to be affected by the presence of RA in that studies have shown higher rates of pericardial effusions in these patients. 7 Activation of the inflammatory cascade via tumor necrosis factor may both accelerate atherosclerosis and induce myocardial or pericardial damage 8 and therefore be responsible for the increased rates of cardiovascular disease in the RA population. As a result, antitumor necrosis factor therapies have been investigated in this population and have resulted in lower rates of both cardiovascular events and overall mortality. 9 Valvular heart disease (VHD) in patients with RA was initially thought to be rare 7, 10, 11 ; however, recent analyses have found that the RA population has a higher incidence of VHD than the general population in that 30% of patients with RA have valvulopathy. 12 However, the impact of RA on the progression on VHD, specifically aortic stenosis (AS), is not well established. AS is common in the elderly population, affecting nearly 1 in 10 patients, 13 and can result in considerable sequelae, including sudden cardiac death. 14 Prior investigations have determined the average annual rate of progression of severity of AS in the general patient population. 15 These findings have informed our current national guidelines for recommendation of subsequent surveillance imaging. Specifically, for patients with mild AS, serial echocardiographic studies are recommended every 3 to 5 years, whereas for patients with moderate AS, echocardiographic assessment is recommended every 1 to 2 years. 14 Unfortunately, such guidelines are lacking in the RA population because of the paucity of studies assessing the rate of AS progression in these patients. Given the aforementioned effects of RA on the cardiovascular system, the inflammatory burden of RA may accelerate the rate of progression of AS in these patients.
Therefore, the primary objective of this study was to determine the rate of progression of AS in patients with RA.
| METHODS

| RA patient population
A retrospective, population-based cohort 16 
| AS patient population
The RA cohort 16 was reviewed for patients who were clinically referred for echocardiographic assessment at our institution. Patients were included in the study if they (1) cardiologist estimated the LVEF. 22 The severity of other valvular lesions was classified in accordance with recommended guidelines.
14,23
| Baseline demographics and comorbidities
Patient age and body surface area were documented at the time the initial echocardiogram was obtained. Smoking history and family history of premature coronary heart disease (defined as the presence of coronary heart disease in first-degree relatives at an age <65 years for females and <55 years for males) were determined at the time of RA diagnosis. Hypertension, hyperlipidemia, and diabetes mellitus were defined based on physician diagnosis, treatment, or standardized criteria, as previously described. 19 Chronic obstructive pulmonary disease and obstructive sleep apnea were based on physician diagnosis. Reduced kidney function was defined as 2 consecutive estimated glomerular filtration rates less than 45 mL/minute per 1.73 m 2 at least 90 days apart using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation. 24 Atrial fibrillation or flutter was based on electrocardiographic findings. Coronary artery disease was defined as the presence of one of the following: angina pectoris, myocardial infarction (including silent events), or coronary revascularization procedures (ie coronary artery bypass graft or percutaneous intervention). Myocardial infarction was defined using standardized epidemiologic criteria, as previously described. Silent myocardial infarction was considered present at the date a characteristic electrocardiogram was first documented or at the date a physician recorded the diagnosis for a patient who had no documented history of myocardial infarction. Heart failure was defined using the Framingham criteria. 25 The Mayo Clinic Institutional Review Board and the Olmsted Medical Center Institutional Review Board approved the study.
| Statistical analysis
Descriptive statistics (eg means, percentages) were used to summarize 
| RESULTS
| Baseline demographics, comorbidities, and echocardiographic data at study onset
Sixty-eight patients met the study's inclusion criteria. The majority of the study population was female (68%), and the mean age at first echocardiogram for all patients was 75 years. The most common comorbidities were hypertension (94%) and hyperlipidemia (88%) ( Table 1) . At the time of the initial echocardiographic assessment, the mean duration of RA in the study population was 13 years, and approximately two-thirds of the patients had been prescribed RA medications at that time (Table 1) . At baseline, 49% of the patients were positive for rheumatoid factor, and serum inflammatory markers were within relatively normal range (Table 1) . Mild AS was present in 88% of patients at baseline, whereas 12% had moderate AS (associated specific AS variables listed in further detail in Table 2 ). The mean LVEF was 63%, and a minority (9%) of patients had an LVEF less than 50%. Mean stroke volume and stroke volume index were within normal limits (Table 2) .
| AS progression
Mean duration of study follow-up (time between baseline and final echocardiogram) was 4.8 years. Peak AV velocity and mean AV gradient increased during the study period (P<.001), whereas AV area and AV dimensionless index decreased (P<.001), consistent with progression of AS (Table 3) On the basis of this model, the estimated annual rates of change were 1.6 and 0.7 mm Hg for ESR values of 45 and 20 mm/hour, respectively ( Figure 1C ). Biologic users experienced smaller increases in peak AV velocity and mean AV valve gradient over time than nonusers, but they had higher peak AV velocity and mean AV valve gradient at initial echocardiography than nonusers, which may indicate confounding by indication (interaction P=.03 and P=.03, respectively).
Methotrexate use at echocardiography was associated with a greater rate of increase in mean AV valve gradient in users than in nonusers (interaction P=.006). Hydroxychloroquine use at echocardiography was associated with a greater rate of decrease in AV dimensionless index in users than in nonusers (interaction P=.04). On Kaplan-Meier estimates, 19% (95% CI, 6% to 30%) of the study population had progression from mild-to-moderate AS after 5 years (only 1 patient had progression from mild to severe during the course of the study), whereas 29% (95% CI, 0% to 55%) had progression from moderate to severe AS 5 years after initial echocardiography.
| DISCUSSION
To our knowledge, this is the only study that has investigated the rate of progression of AS in the RA population. Given the increasing incidence of both AS 13 and RA 2 in the elderly population and current national demographic trends, the prevalence of patients with RA who present with AS will likely continue to increase. Therefore, it is critical to ascertain the rate of progression of AS in this unique popula- inflammatory phase characterized by low-density lipoprotein accumulation and oxidation 30, 31 and increased interleukin-1β and transforming growth factor-1β signaling 32, 33 with resultant macrophage and lymphocyte aortic tissue infiltration. 34, 35 However, although this inflammatory model may be the mechanism for the development of AS, a distinct pathophysiologic mechanism has been postulated to be responsible for the actual progression of AS and is predicated on pathologic and imaging studies finding that pro-calcific pathways induce the accumulation of cartilage and bone on the AV.
This model, in which inflammation leads to development of calcific AS but a separate pathophysiologic pathway involved with bone formation leads to progression of AS, may help to elucidate the findings of both prior RA and VHD studies and our study. For example, studies 12, 36 have found a high incidence of VHD in the RA population, and this could be due to the increased inflammatory state present in these patients. However, the progression of AS, which is dependent on cartilage and bone formation, may be uniquely inhibited in the RA population because of the presence of tumor necrosis factor and interleukin-1, which incite osteoclast activation and ultimately bone resorption. 37 More detailed molecular studies and further understanding of the pathophysiologic mechanism underpinning the progression of AS in the RA population are needed to more fully understand the disease process.
A potential alternative explanation to our finding that progression of AS in patients with RA is less than that in the general population may be the use of immunosuppressive therapy in our study population. If inflammation at least drives the initial phases of AS, then the use of systemic anti-inflammatory agents in the RA population may actually serve to limit AS progression more so than in the general population, who are less likely to be receiving immunosuppressive therapy. This hypothesis is supported by our finding that the rate of AS progression was higher in patients who had an increased ESR.
| Limitations
The population-based design of the study with extensive follow-up and the use of complete (inpatient and outpatient) contemporary medical record documentation strengthens our work by providing complete ascertainment of study outcomes. However, echocardiography was completed as part of routine clinical practice, and as a result, patients with subclinical disease may not have been identified.
Although we did not have a comparison group, we compared the results of our study with the known AS progression rates described in the general population. 15, [26] [27] [28] [29] Whether any of these studies included patients with RA was not reported, but, if present, their percentage of the total study population is likely small. Our study focused on mild and moderate AS given that we wanted to understand the rate of progression of AS in these patients so as to inform clinical decision making about when repeat surveillance imaging might be warranted.
Assessment of the rate of progression of severe AS in the RA population would be of interest in future studies. The trials assessing AS progression in the general population have ranged from including patients with only moderate or greater AS 15 to including the entire spectrum of AS (mild, moderate, and severe). 29 Finally, this study evaluated patients who were being treated or evaluated for RA who had relatively normal levels of systemic inflammatory markers throughout the duration of the study, and therefore, the impact of untreated disease on AS progression cannot be derived from our study cohort.
| CONCLUSION
The progression of AS in the RA population has not previously been investigated. This study found that the rate of progression of AS in F I G U R E 1 Rate of progression of aortic stenosis according to age and erythrocyte sedimentation rate (ESR). A and B, Association of aortic valve (AV) area and dimensionless index with age in years. C, Association of mean AV gradient with ESR (mm/hour) patients with RA is less than that in the general population. The exact mechanism for this finding is uncertain. Regardless of potential cause, the finding that AS progression in the RA population is no more severe than that in the general population indicates that adherence to current recommended echocardiographic surveillance guidelines for mild AS (every 3-5 years) and moderate AS (every 1-2 years) 14 is reasonable in the patient with RA who has AS.
